TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Capstone Therapeutics ( (CAPS) ) has shared an update.
On August 22, 2025, Capstone Holding Corp. completed its acquisition of Carolina Stone Holdings, LLC, and its subsidiary, Carolina Stone Distributors, LLC, from D22L, Inc. and other sellers. The transaction involved a cash payment of $2,625,000, subject to adjustments, and a seller note of $1,250,000. This acquisition is expected to enhance Capstone’s market presence in the stone products industry by expanding its operational capabilities and market reach.
The most recent analyst rating on (CAPS) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Capstone Therapeutics stock, see the CAPS Stock Forecast page.
Spark’s Take on CAPS Stock
According to Spark, TipRanks’ AI Analyst, CAPS is a Neutral.
Capstone Therapeutics’ overall stock score is primarily impacted by its weak financial performance and poor valuation metrics. The company’s declining revenue, negative equity, and high leverage present significant financial risks. Technical analysis indicates bearish momentum, further contributing to the low score. The absence of earnings call data and corporate events does not alter the overall assessment.
To see Spark’s full report on CAPS stock, click here.
More about Capstone Therapeutics
Capstone Therapeutics operates within the stone products industry, focusing on the sale and distribution of stone products and the installation of stonework in residential and commercial properties through its Carolina Stone Companies.
Average Trading Volume: 2,463,810
Technical Sentiment Signal: Sell
Current Market Cap: $7.64M
For detailed information about CAPS stock, go to TipRanks’ Stock Analysis page.